Ridinilazole: a novel therapy for Clostridium difficile infection

Richard J. Vickers, Glenn Tillotson, Ellie J.C. Goldstein, Diane M. Citron, Kevin W. Garey, Mark H. Wilcox
2016 International Journal of Antimicrobial Agents  
A B S T R A C T Clostridium difficile infection (CDI) is the leading cause of infectious healthcare-associated diarrhoea. Recurrent CDI increases disease morbidity and mortality, posing a high burden to patients and a growing economic burden to the healthcare system. Thus, there exists a significant unmet and increasing medical need for new therapies for CDI. This review aims to provide a concise summary of CDI in general and a specific update on ridinilazole (formerly SMT19969), a novel
more » ... terial currently under development for the treatment of CDI. Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay antibiotics for CDI. Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect. Furthermore, treatment with ridinilazole results in decreased toxin production. A phase 1 trial demonstrated that oral ridinilazole is well tolerated and specifically targets clostridia whilst sparing other faecal bacteria. Phase 2 and 3 trials will hopefully further our understanding of the clinical utility of ridinilazole for the treatment of CDI.
doi:10.1016/j.ijantimicag.2016.04.026 pmid:27283730 fatcat:w66gark3xjbdxl66g5xezparbu